Advice

in the absence of a submission from the holder of the marketing authorisation

daratumumab (Darzalex®) is not recommended for use within NHSScotland.


Indication under review: in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice355KB (PDF)

Download

Medicine details

Medicine name:
daratumumab (Darzalex)
SMC ID:
SMC2191
Indication:
In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
13 May 2019